Connect with RxStrategies During the NACHC’s 2016 Policy & Issues Forum
RxStrategies will be attending the NACHC’s 2016 Policy & Issues Forum from March 16 – 19. Rhodie Smith and the RxStrategies’ team are looking forward to connecting with health center leaders and decision-makers and public health leaders in the heart of Washington, D.C. to focus on the nation’s healthcare. During the meeting, they will be…
Clinical Insights — March 2016 Issue
Welcome to the March edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Briviact® (brivaracetam) February 19, 2016 – The U.S. Food and Drug Administration (FDA) approved Briviact® (brivaracetam) as an add-on treatment to other medications to treat partial onset…
RxStrategies Clinical Insights — November Issue 1
Welcome to the first November edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Imlygic™ (talimogene laherparepvec) October 27, 2015 — The U.S. Food and Drug Administration approved Imlygic™ (talimogene laherparepvec), the first FDA-approved oncolytic virus therapy, for the…
Become Part of the RxStrategies Team
Looking for a new career? RxStrategies is currently seeking Account Managers. Learn more.
RxStrategies Clinical Insights — August 2015 Issue 1
Welcome to the August edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Odomzo® (sonidegib) July 24, 2015 — The U.S. Food and Drug Administration approved Odomzo® (sonidegib) to treat patients with locally advanced basal cell carcinoma that…
RxStrategies Clinical Insights — June/July Issue 1
Welcome to the June/July edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Kengreal™ (cangrelor) June 22, 2015 — The U.S. Food and Drug Administration approved Kengreal™ (cangrelor), an intravenous antiplatelet drug that prevents formation of harmful blood…
June 340B Insider
Welcome to the June edition of RxStrategies 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view. 340B UPDATES 21st Century Cures Act Moves Forward Without 340B Language On May 21, the House Energy and Commerce Committee unanimously approved the 21st Century Cures Act (H.R. 6) without the inclusion of…
RxStrategies Clinical Insights – May 2015 Issue 2
Welcome to May’s second edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Viberzi™ (eluxadoline) May 27, 2015 — Actavis plc announced Viberzi™ (eluxadoline) was approved by the Food and Drug Administration as a twice-daily, oral treatment for…
RxStrategies Clinical Insights – May 2015 Issue 1
Welcome to the May edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approvals Kybella™ (deoxycholic acid) April 29, 2015 – The U.S. Food and Drug Administration approved Kybella™ (deoxycholic acid), a treatment for adults with moderate-to-severe fat below…
RxStrategies Clinical Insights – April 2015 Issue 1
Welcome to the April edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approvals Corlanor® (ivabradine) April 15, 2015 – The U.S. Food and Drug Administration approved Corlanor® (ivabradine) to reduce hospitalization from worsening heart failure. Corlanor® is approved for use…
RxStrategies Clinical Insights – March Issue 2
Welcome to the March second edition of RxStrategies Clinical Insights, a concise communication to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approvals Anthrasil™ (Anthrax Immune Globulin Intravenous – Human) – New Drug Approval March 25, 2015 – The U.S. Food and Drug Administration approved…
RxS Team Connects with Attendees during the NACHC Policy & Issues Forum
Connect with Mary Ellen England and Rhodie Smith at Booth # 217 during the conference!